Brazil has suspended its dengue vaccination programme linked to the Butantan Institute, with health authorities characterising the halt
as a precautionary measurewhile an investigation into safety concerns is carried out, according to a World Report published by The Lancet on 20 June 2026.
What Is Known About the Suspension
The decision to pause immunisations was framed by Brazilian health authorities as a cautious response rather than a confirmed finding of harm. The Lancet's report, authored by Lise Alves, notes that a safety investigation is underway, though no specific clinical or epidemiological details regarding the nature of the concerns have been made publicly available at this stage.
The Butantan Institute, a prominent Brazilian biomedical research centre, had been central to the country's dengue immunisation efforts. The scope of the suspension — including which age groups or regions are affected — was not detailed in the available reporting.
Context Around Dengue Vaccination in Brazil
Dengue fever remains a significant public health burden in Brazil, a country that has historically recorded some of the world's highest annual case counts. Vaccination programmes targeting the disease have been a key component of national efforts to reduce transmission and severe illness.
Precautionary suspensions of vaccine programmes are not uncommon during post-market surveillance phases, when regulators monitor real-world outcomes beyond the controlled conditions of clinical trials. Such pauses allow health agencies to gather additional data before deciding whether to resume, modify, or discontinue a programme.
Investigation Ongoing
As of the report's publication, the safety investigation remained active. No conclusions had been drawn, and no further detail on the investigation's timeline or scope was provided in The Lancet's coverage. The precautionary framing used by authorities suggests the suspension was initiated before any definitive adverse signal had been confirmed.
The Lancet's World Report did not indicate whether the suspension applied solely to new doses or also affected scheduled follow-up immunisations for individuals already partway through a vaccination course.
Further updates are expected as the investigation progresses.